<scp>KAT2A</scp> Promotes the Progression of Renal Cell Carcinoma by Regulating the Succinylation of <scp>SERPINE2</scp>

Epithelial-mesenchymal transition (EMT) and angiogenesis are critical drivers of renal cell carcinoma (RCC) progression, yet their upstream regulatory mechanisms remain incompletely understood. This study aimed to investigate the role of KAT2A in RCC and elucidate the underlying molecular mechanism by which it promotes tumor progression. To investigate KAT2A and SERPINE2 in RCC, we assessed their expression and downstream effects using real-time quantitative PCR and western blot. EMT markers (E-cadherin, N-cadherin, Vimentin) and SERPINE2 succinylation were also measured. Functional assays (CCK-8, colony formation, transwell, tube formation) evaluated cell viability, proliferation, migration, and angiogenesis. Co-localization (immunofluorescence) and interaction (co-immunoprecipitation) of KAT2A and SERPINE2 were confirmed. Finally, Ki-67, KAT2A, and SERPINE2 expression in RCC tumors were examined via immunohistochemistry. We identified that KAT2A expression was significantly elevated in RCC tissues and correlated with poor patient prognosis. Functionally, KAT2A depletion markedly inhibited RCC cell proliferation, migration, EMT, and HUVECs angiogenesis in vitro, as well as suppressed tumor growth in vivo. Mechanistically, KAT2A directly interacted with SERPINE2 and promoted its succinylation at lysine 158 (K158). This post-translational modification enhanced SERPINE2 protein stability, and SERPINE2 overexpression effectively reversed the tumor-suppressive effects induced by KAT2A silencing. Our findings reveal that the KAT2A/SERPINE2 axis is a key regulator of RCC pathogenesis, identifying KAT2A-mediated SERPINE2 succinylation as a novel mechanism and potential therapeutic target for RCC treatment.